Meslamani J - Search Results

1

The bromodomain: from epigenome reader to druggable target.

Sanchez R, Meslamani J, Zhou MM. Sanchez R, et al. Among authors: meslamani j. Biochim Biophys Acta. 2014 Aug;1839(8):676-85. doi: 10.1016/j.bbagrm.2014.03.011. Epub 2014 Mar 28. Biochim Biophys Acta. 2014. PMID: 24686119 Free PMC article. Review.

2

Structural features and inhibitors of bromodomains.

Meslamani J, Smith SG, Sanchez R, Zhou MM. Meslamani J, et al. Drug Discov Today Technol. 2016 Mar;19:3-15. doi: 10.1016/j.ddtec.2016.09.001. Epub 2016 Sep 22. Drug Discov Today Technol. 2016. PMID: 27769355 Free PMC article. Review.

3

Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.

Yang X, Li F, Konze KD, Meslamani J, Ma A, Brown PJ, Zhou MM, Arrowsmith CH, Kaniskan HÜ, Vedadi M, Jin J. Yang X, et al. Among authors: meslamani j. J Med Chem. 2016 Aug 25;59(16):7617-33. doi: 10.1021/acs.jmedchem.6b00855. Epub 2016 Aug 11. J Med Chem. 2016. PMID: 27468126 Free PMC article.

4

ChEpiMod: a knowledgebase for chemical modulators of epigenome reader domains.

Meslamani J, Smith SG, Sanchez R, Zhou MM. Meslamani J, et al. Bioinformatics. 2014 May 15;30(10):1481-3. doi: 10.1093/bioinformatics/btu052. Epub 2014 Jan 27. Bioinformatics. 2014. PMID: 24470572 Free PMC article.

5

BET N-terminal bromodomain inhibition selectively blocks Th17 cell differentiation and ameliorates colitis in mice.

Cheung K, Lu G, Sharma R, Vincek A, Zhang R, Plotnikov AN, Zhang F, Zhang Q, Ju Y, Hu Y, Zhao L, Han X, Meslamani J, Xu F, Jaganathan A, Shen T, Zhu H, Rusinova E, Zeng L, Zhou J, Yang J, Peng L, Ohlmeyer M, Walsh MJ, Zhang DY, Xiong H, Zhou MM. Cheung K, et al. Among authors: meslamani j. Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):2952-2957. doi: 10.1073/pnas.1615601114. Epub 2017 Mar 6. Proc Natl Acad Sci U S A. 2017. PMID: 28265070 Free PMC article.

6

Spatially constrained tandem bromodomain inhibition bolsters sustained repression of BRD4 transcriptional activity for TNBC cell growth.

Ren C, Zhang G, Han F, Fu S, Cao Y, Zhang F, Zhang Q, Meslamani J, Xu Y, Ji D, Cao L, Zhou Q, Cheung KL, Sharma R, Babault N, Yi Z, Zhang W, Walsh MJ, Zeng L, Zhou MM. Ren C, et al. Among authors: meslamani j. Proc Natl Acad Sci U S A. 2018 Jul 31;115(31):7949-7954. doi: 10.1073/pnas.1720000115. Epub 2018 Jul 16. Proc Natl Acad Sci U S A. 2018. PMID: 30012592 Free PMC article.

7

sc-PDB: a database for identifying variations and multiplicity of 'druggable' binding sites in proteins.

Meslamani J, Rognan D, Kellenberger E. Meslamani J, et al. Bioinformatics. 2011 May 1;27(9):1324-6. doi: 10.1093/bioinformatics/btr120. Epub 2011 Mar 12. Bioinformatics. 2011. PMID: 21398668

8

Protein-ligand-based pharmacophores: generation and utility assessment in computational ligand profiling.

Meslamani J, Li J, Sutter J, Stevens A, Bertrand HO, Rognan D. Meslamani J, et al. J Chem Inf Model. 2012 Apr 23;52(4):943-55. doi: 10.1021/ci300083r. Epub 2012 Apr 11. J Chem Inf Model. 2012. PMID: 22480372

9

Enhancing the accuracy of chemogenomic models with a three-dimensional binding site kernel.

Meslamani J, Rognan D. Meslamani J, et al. J Chem Inf Model. 2011 Jul 25;51(7):1593-603. doi: 10.1021/ci200166t. Epub 2011 Jun 21. J Chem Inf Model. 2011. PMID: 21644501

10

Assessing the geometric diversity of cytochrome P450 ligand conformers by hierarchical clustering with a stop criterion.

Meslamani JE, André F, Petitjean M. Meslamani JE, et al. J Chem Inf Model. 2009 Feb;49(2):330-7. doi: 10.1021/ci800275k. J Chem Inf Model. 2009. PMID: 19434834

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results